The Role Of Metformin, Magnesium, And Vitamin D In Modulating Redox Enzymes In Streptozotocin-Induced Diabetes: An Albino Rat Model Study

Abstract

This study investigates the role of metformin, magnesium, and vitamin D in modulating redox enzymes in streptozotocin-induced diabetes, employing an albino rat model. While numerous studies have explored the impact of metformin therapy in combination with various vitamins, there is a noticeable scarcity of research examining the effects of metformin therapy in conjunction with a combination of various vitamins along with manganese. The experimental design involved six groups of rats, each comprising six individuals. The control group (Group 1) served as the baseline, while Group 2 represented untreated diabetes induced by streptozotocin (DU). Group 3 received metformin for diabetes treatment (DTM), Group 4 received a combination of metformin and vitamin D (DTMV-D), Group 5 received a combination of metformin and magnesium (DTMM), and Group 6 received a combination of metformin, vitamin D, and magnesium (DTMMV-D).The organs, particularly the liver and kidney, were isolated after treatment for enzyme assays, including lactate dehydrogenase (LDH), succinate dehydrogenase (SDH), and glucose-6-phosphate dehydrogenase (G-6-PDH). Results demonstrated that untreated diabetes led to significant increases in SDH, LDH, and G-6-PDH activities compared to the control group. While metformin treatments showed varying degrees of effectiveness in restoring these enzyme activities, the combination of metformin, vitamin D, and magnesium (DTMMV-D) consistently stood out, indicating potential benefits in mitigating diabetes-induced changes in redox enzyme levels. The study contributes valuable insights into the complex interplay of these treatments with redox enzymes, offering a foundation for future research on innovative therapeutic strategies in diabetes management.